NDAORALSOLUTION
Approved
Jan 2026
Lifecycle
Launch
Competitive Pressure
30/100
Clinical Trials
16
Data completeness
4/8 — Partial
QUIOFIC (folic acid) by Teva is clinical pharmacology folic acid acts on megaloblastic bone marrow to produce a normoblastic marrow. Approved for rheumatoid arthritis, neural tube defects, pregnancy. First approved in 2026.
Drug data last refreshed 20h ago
Mechanism of Action
CLINICAL PHARMACOLOGY Folic acid acts on megaloblastic bone marrow to produce a normoblastic marrow. In man, an exogenous source of folate is required for nucleoprotein synthesis and the maintenance of normal erythropoiesis. Folic acid is the precursor of tetrahydrofolic acid, which is involved as…
Worked on QUIOFIC at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.